Literature DB >> 9343192

Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

D Matteucci1, M Pistello, P Mazzetti, S Giannecchini, D Del Mauro, I Lonetti, L Zaccaro, C Pollera, S Specter, M Bendinelli.   

Abstract

Cats immunized with cells infected with a primary isolate of feline immunodeficiency virus (FIV) and fixed with paraformaldehyde were challenged with cell-free or cell-associated homologous virus obtained ex vivo. Complete protection was observed in animals challenged with cell-free virus 4 months after completion of vaccination (p.v.) or with cell-associated virus 12 months p.v. In contrast, no protection was observed in cats challenged with cell-free virus 12 or 28 months p.v. or with cell-associated virus 37.5 months p.v. Prior to the 28- and 37.5-month challenges, the animals had received a booster dose of vaccine that had elicited a robust anamnestic immune response. These results show that vaccine-induced protection against ex vivo FIV is achievable but is relatively short-lived and can be difficult to boost.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343192      PMCID: PMC192298     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Anti-cell antibody in macaques.

Authors:  E J Stott
Journal:  Nature       Date:  1991-10-03       Impact factor: 49.962

2.  Reduced sensitivity to strain-specific neutralization of laboratory-adapted feline immunodeficiency virus after one passage in vivo: association with amino acid substitutions in the V4 region of the surface glycoprotein.

Authors:  G Cammarota; D Matteucci; M Pistello; E Nicoletti; S Giannecchini; M Bendinelli
Journal:  AIDS Res Hum Retroviruses       Date:  1996-01-20       Impact factor: 2.205

Review 3.  Antibody neutralization of HIV-1.

Authors:  P Poignard; P J Klasse; Q J Sattentau
Journal:  Immunol Today       Date:  1996-05

4.  Analysis of the genetic diversity and phylogenetic relationship of Italian isolates of feline immunodeficiency virus indicates a high prevalence and heterogeneity of subtype B.

Authors:  M Pistello; G Cammarota; E Nicoletti; D Matteucci; M Curcio; D Del Mauro; M Bendinelli
Journal:  J Gen Virol       Date:  1997-09       Impact factor: 3.891

5.  Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response.

Authors:  S A Bishop; C R Stokes; T J Gruffydd-Jones; C V Whiting; J E Humphries; R Osborne; M Papanastasopoulou; D A Harbour
Journal:  Vaccine       Date:  1996-09       Impact factor: 3.641

6.  Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

Authors:  M J Hosie; J N Flynn
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

7.  Immunogenicity of a peptide from a major neutralising determinant of the feline immunodeficiency virus surface glycoprotein.

Authors:  M A Rigby; N Mackay; G Reid; R Osborne; J C Neil; O Jarrett
Journal:  Vaccine       Date:  1996-08       Impact factor: 3.641

8.  Quantitation of feline immunodeficiency proviruses in doubly infected cats using competitive PCR and a fluorescence-based RFLP.

Authors:  G Cammarota; L Da Prato; E Nicoletti; D Matteucci; M Bendinelli; M Pistello
Journal:  J Virol Methods       Date:  1996-10       Impact factor: 2.014

9.  Incubation time for feline immunodeficiency virus cultures.

Authors:  S Giannecchini; D Matteucci; P Mazzetti; M Bendinelli
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

10.  Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.

Authors:  V M Hirsch; T R Fuerst; G Sutter; M W Carroll; L C Yang; S Goldstein; M Piatak; W R Elkins; W G Alvord; D C Montefiori; B Moss; J D Lifson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more
  14 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

Authors:  S Giannecchini; D Del Mauro; D Matteucci; M Bendinelli
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.

Authors:  Giulia Freer; Donatella Matteucci; Paola Mazzetti; Francesca Tarabella; Valentina Catalucci; Enrica Ricci; Antonio Merico; Leonia Bozzacco; Mauro Pistello; Mauro Bendinelli
Journal:  Clin Vaccine Immunol       Date:  2008-01-23

4.  Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.

Authors:  D Del Mauro; D Matteucci; S Giannecchini; F Maggi; M Pistello; M Bendinelli
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 5.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats.

Authors:  D Matteucci; A Poli; P Mazzetti; S Sozzi; F Bonci; P Isola; L Zaccaro; S Giannecchini; M Calandrella; M Pistello; S Specter; M Bendinelli
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.